Breast cancer: Neoadjuvant bevacizumab treatment - Signal or noise?

Abstract

Neoadjuvant bevacizumab, when added to standard chemotherapy for operable breast cancer, improved the rate of complete pathological response in two large, well-conducted trials. However, the modest incremental benefits, combined with uncertain long-term effects on disease recurrence, mean that this approach remains experimental until follow-up data are available. © 2012 Macmillan Publishers Limited. All rights reserved.